- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03043560
Study to Treat Major Depressive Disorder With a New Medication
Developing Neuronal KCNQ Channel Modulators for Mood Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depressive disorders are among the most disabling medical conditions worldwide and currently available treatments fall short of addressing this large public health burden. Dysfunction within the brain reward system is emerging as a core feature of depressive disorders, in particular related to deficits in motivation, interest, and response to pleasure (e.g., anhedonia: markedly diminished response to pleasure). Evidences from a series of preclinical studies from our group highlighted the KCNQ subtype of neuronal potassium (K+) channel as a novel target for the treatment of depressive disorders and our human pilot study showed a reduction in anhedonia and related symptoms, and an increased brain response to reward (as measured by functional magnetic resonance imaging [fMRI]) following treatment with ezogabine. Building on this data, the current project will assess reward circuit activity following treatment with ezogabine in depressed patients with a current depressive disorder (Major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) and anhedonia (defined by a score ≥ 20 on the Snaith-Hamilton Pleasure Scale [SHAPS]), using fMRI to investigate the cortico-striatal circuit to reward.
This study represents the first part of the R61/R33 National Institutes of Health (NIH) founded project. A clear increase in reward circuit activation in at least one ezogabine treatment group compared to placebo, given acceptable tolerability, will constitute a "go" and the project will move to the next phase (R33), where we aim to examine the relationship between treatment, reward circuit activity, and behavioral and clinical outcomes in a larger, confirmatory efficacy trial of ezogabine for depression with anhedonia.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study;
- Men and women, age 18-65;
- Participants must meet DSM-V criteria for current depressive disorder (major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-V (SCID);
- Clinically significant anhedonia as determined by a SHAPS score ≥ 20 at screening;
- Current illness severity is at least moderate, defined as a score of ≥4 on the Clinical Global Impression-Severity (CGI-S) Scale;
- If female of childbearing potential, must agree to use of a medically accepted form of contraception, or else agree to abstinence.
Exclusion Criteria:
- A primary psychiatric diagnosis other than a depressive disorder as defined by DSM-V [co-morbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder and panic disorder) and Posttraumatic Stress Disorder (PTSD) are allowed] or major cognitive disorder;
- Meets criteria for a substance or alcohol use disorder in the past 6 months;
- Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study;
- Positive urine toxicology screen for drugs of abuse at the time of screening;
- Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease;
- Clinically significant abnormalities of laboratory tests, physical examination, or ECG;
- Prolonged QT Interval at screening, operationalized as a QTc of > 480 ms;
- A history of retinal abnormalities (i.e., pigment changes, retinal dystrophy) or findings of retinal pathology on ophthalmological exam at baseline;
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data;
- Use of any dis-allowed medication according to the study protocol;
- Serious and imminent risk of self harm or violence as determined by the PI;
- Extreme illness severity as defined by a GCI-S score >6;
- Any contraindication to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
History of non-response to electroconvulsive therapy in the current depressive episode
Exceptions:
- Subjects with a positive urine drug screen for cannabinoids, barbiturates, opiates, amphetamines, or benzodiazepines may be allowed in the study provided that the drug was used for a documented, legitimate medical purpose and/or the use of such products may be discontinued (documented by a negative repeat test) prior to randomization;
Medically appropriate episodic use (up to 3 days) of narcotic analgesics for acute medical indications is allowed (Discussion with PI required)
- Potential participants will not be discontinued from medication for the purposes of this study. If a patient is taking a protocol dis-allowed medication at the time of screening, the patient may discontinue the medication under the supervision of the treating physician in the case that the patient is not benefiting from the medication or otherwise wishes to discontinue the medication. In no case will a dis-allowed medication be discontinued for the purpose of study participation if the patient is receiving clinical benefit from the medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ezogabine
Participants will receive treatment with ezogabine up to 900mg/day.
|
daily for 5 weeks
Other Names:
|
Placebo Comparator: Placebo
Participants will receive treatment with a matching placebo pill.
|
placebo pill daily for 5 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Ventral Striatum (VS) Activation
Time Frame: baseline and 5 weeks
|
change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive. Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate. |
baseline and 5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
Time Frame: baseline and 5 weeks
|
The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia.
Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity.
A total score can be derived by summing the responses to each item.
Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4."
Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
|
baseline and 5 weeks
|
Clinical Global Impression - Improvement (CGI-I)
Time Frame: baseline and 5 weeks
|
A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity.
7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
|
baseline and 5 weeks
|
Clinical Global Impression - Severity (CGI-S)
Time Frame: baseline and 5 weeks
|
Clinician rated global measure of subject overall illness severity.
a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
|
baseline and 5 weeks
|
Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
Time Frame: baseline and 5 weeks
|
A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me).
Full scale from 17-102, higher score indicates higher hedonic capacity
|
baseline and 5 weeks
|
Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: baseline and 5 weeks
|
A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms.
Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).
|
baseline and 5 weeks
|
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: baseline and 5 weeks
|
A 12-item generic assessment instrument that measures the level of functioning.
Each item is scored from 0 to 4 and the items are summed to provide a total score.
The score therefore ranges from 0 to 48, with higher scores indicating greater disability.
|
baseline and 5 weeks
|
Temporal Experience of Pleasure Scale (TEPS)
Time Frame: baseline and 5 weeks
|
The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales.
Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated).
The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive).
Total scores range is 18-108.
Lower scores indicate greater levels of anhedonia.
|
baseline and 5 weeks
|
Specific Loss of Interest and Pleasure Scale (SLIPS)
Time Frame: baseline 5 weeks
|
The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia.
A 23-item measure, each item range from 0-3.
Full scale from 0 to 69, higher score indicates more recent changes.
|
baseline 5 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 16-0374
- 1R61MH111932-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
Clinical Trials on Ezogabine
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedEpilepsyUnited States, Canada, Argentina, Brazil, Mexico
-
GlaxoSmithKlineBausch Health Americas, Inc.Terminated
-
GlaxoSmithKlineBausch Health Americas, Inc.Terminated
-
Xenon Pharmaceuticals Inc.TerminatedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in ChildrenUnited States, Spain, Australia, Belgium, Italy
-
University Hospital of Mont-GodinneGlaxoSmithKline; Université Catholique de LouvainCompleted
-
GlaxoSmithKlineCompleted
-
Icahn School of Medicine at Mount SinaiCompletedDepression | Major Depressive DisorderUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineBausch Health Americas, Inc.TerminatedSeizuresUnited States, Greece